Mesoblast Ltd Cash Flow Conversion Efficiency
Mesoblast Ltd cash flow conversion efficiency. Based on the latest financial reports, Mesoblast Ltd (MESO) has a cash flow conversion efficiency ratio of -0.016x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.26 Million) by net assets ($568.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mesoblast Ltd (2005–2026)
Cash flow conversion efficiency of Mesoblast Ltd from 2005 to 2026. This chart illustrates how Mesoblast Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Mesoblast Ltd stock quote for real-time trading data and today's change.
Mesoblast Ltd Cash Flow Conversion Ratio Explained
Mesoblast Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mesoblast Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mesoblast Ltd ranked by their cash flow conversion efficiency. Also see Mesoblast Ltd (MESO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grupo Profuturo S.A.B. de C.V
MX:GPROFUT
|
0.044x |
|
Dermapharm Holding SE
XETRA:DMP
|
0.054x |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
0.102x |
|
CleanSpark Inc
NASDAQ:CLSK
|
-0.148x |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
-0.004x |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
0.075x |
|
Snowline Gold Corp.
V:SGD
|
N/A |
|
HCI Group Inc
NYSE:HCI
|
0.168x |
Annual Cash Flow Conversion Efficiency for Mesoblast Ltd (2005–2026)
The table below shows the annual cash flow conversion efficiency of Mesoblast Ltd from 2005 to 2026. Review MESO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $568.40 Million | $-43.83 Million | -0.077x | +7.78% |
| 2025-06-30 | $597.44 Million | $-49.95 Million | -0.084x | +17.12% |
| 2024-06-30 | $480.36 Million | $-48.46 Million | -0.101x | +19.98% |
| 2023-06-30 | $501.84 Million | $-63.27 Million | -0.126x | +4.74% |
| 2022-06-30 | $497.04 Million | $-65.78 Million | -0.132x | +27.87% |
| 2021-06-30 | $581.40 Million | $-106.68 Million | -0.183x | -78.83% |
| 2020-06-30 | $549.33 Million | $-56.37 Million | -0.103x | +14.59% |
| 2019-06-30 | $481.05 Million | $-57.79 Million | -0.120x | +12.56% |
| 2018-06-30 | $546.01 Million | $-75.01 Million | -0.137x | +25.64% |
| 2017-06-30 | $516.77 Million | $-95.47 Million | -0.185x | -10.89% |
| 2016-06-30 | $528.16 Million | $-88.00 Million | -0.167x | +16.58% |
| 2015-06-30 | $609.36 Million | $-121.71 Million | -0.200x | -39.49% |
| 2014-06-30 | $571.72 Million | $-81.86 Million | -0.143x | -66.87% |
| 2013-06-30 | $630.27 Million | $-54.08 Million | -0.086x | +43.03% |
| 2012-06-30 | $478.85 Million | $-72.12 Million | -0.151x | -171.78% |
| 2011-06-30 | $515.84 Million | $108.23 Million | 0.210x | +182.38% |
| 2010-06-30 | $37.92 Million | $-9.66 Million | -0.255x | +28.89% |
| 2009-06-30 | $25.79 Million | $-9.24 Million | -0.358x | -51.39% |
| 2008-06-30 | $26.22 Million | $-6.20 Million | -0.237x | +46.61% |
| 2007-06-30 | $20.54 Million | $-9.10 Million | -0.443x | -66.55% |
| 2006-06-30 | $11.97 Million | $-3.18 Million | -0.266x | -747.50% |
| 2005-06-30 | $19.26 Million | $-604.81K | -0.031x | -- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid … Read more